Agios Pharmaceuticals (AGIO) EBT (2016 - 2025)
Historic EBT for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to -$109.1 million.
- Agios Pharmaceuticals' EBT fell 346.87% to -$109.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$415.6 million, marking a year-over-year decrease of 15814.19%. This contributed to the annual value of -$413.8 million for FY2025, which is 15763.44% down from last year.
- Per Agios Pharmaceuticals' latest filing, its EBT stood at -$109.1 million for Q4 2025, which was down 346.87% from -$103.4 million recorded in Q3 2025.
- Agios Pharmaceuticals' 5-year EBT high stood at $1.0 billion for Q3 2024, and its period low was -$112.5 million during Q2 2025.
- Over the past 5 years, Agios Pharmaceuticals' median EBT value was -$92.0 million (recorded in 2022), while the average stood at -$39.4 million.
- In the last 5 years, Agios Pharmaceuticals' EBT surged by 119613.57% in 2024 and then plummeted by 11033.26% in 2025.
- Over the past 5 years, Agios Pharmaceuticals' EBT (Quarter) stood at -$98.6 million in 2021, then increased by 5.98% to -$92.7 million in 2022, then fell by 3.51% to -$95.9 million in 2023, then decreased by 9.86% to -$105.4 million in 2024, then decreased by 3.47% to -$109.1 million in 2025.
- Its last three reported values are -$109.1 million in Q4 2025, -$103.4 million for Q3 2025, and -$112.5 million during Q2 2025.